Circulating Biomarkers for Early Cancer Detection and Treatment

Edited by:

Agnese Po, PhD, Sapienza University of Rome, Italy

Submission Status: Open | Submission Deadline: 12 November 2025

Illustration of Next-generation Diagnostic Tools Cancer Cell International is calling for submissions to our Collection on Circulating Biomarkers for Early Cancer Detection and Treatment. This Collection invites original research articles with a strong focus on underlying mechanisms or experimental studies, aiming to highlight novel findings in liquid biopsy technologies and their implications for personalized cancer care, ultimately contributing to improved patient outcomes and innovative healthcare solutions. The submission of relevant reviews and comments is also welcome.

Image credit: © ArtemisDiana / Getty Images / iStock

New Content Item This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being.

Submit to Collection

Meet the Guest Editor

Back to top

Agnese Po, PhD, Sapienza University of Rome, Italy

Photo of Agnese Po Dr Agnese Po is an Associate Professor of Biotechnology and Methods in Laboratory Medicine at Sapienza University of Rome, specializing in molecular oncology and non-coding RNAs. Her research focuses on understanding the mechanisms driving tumor development and progression, with particular attention to the roles of non-coding RNAs. She has also extensively studied circulating biomarkers, such as microRNAs and cell-free DNA (cfDNA), to identify new molecular markers for disease detection, prognosis, and therapy monitoring.

About the Collection

The advancement of our collective understanding of circulating biomarkers for early cancer detection and treatment is essential for improving patient outcomes. Recent breakthroughs in liquid biopsy technologies have enabled the identification of circulating tumor DNA and other biomarkers, providing a non-invasive means to monitor tumor progression and response to therapy. These advances have the potential to revolutionize cancer diagnostics and treatment paradigms.

A thorough understanding of the molecular mechanisms underlying cancer biology is vital for developing personalized treatment plans tailored to an individual’s unique biomarker profile, ultimately enhancing the precision of cancer care.

We invite researchers to submit their work to our Collection on Circulating Biomarkers for Early Cancer Detection and Treatment. This Collection aims to showcase research that delves into various aspects of circulating biomarkers, with a particular emphasis on underlying mechanisms and experimental studies in vitro/in vivo. We welcome submissions that include, but are not limited to:

•   Liquid biopsy applications in oncology
•   Novel circulating biomarkers for early detection
•   Machine Learning in Biomarker Discovery
•   Molecular mechanisms of tumor progression
•   Studies of circulating biomarkers in vitro, in two- or three-dimensional systems, or in vivo
•   Biomarkers in cancer treatment response
•   Integrating biomarkers into clinical practice
•   Minimal Residual Disease Monitoring
•   Translational Research in Oncology
•   Circulating Tumor DNA Analysis
•   Early Detection Strategies

Acceptable article types include research articles with a strong focus on underlying mechanisms or experimental studies. The submission of relevant reviews and comments is also welcome.

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original research articles, reviews and comments. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal.

Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Circulating Biomarkers for Early Cancer Detection and Treatment" under the “Details” tab during the submission stage.

Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.